問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Pediatrics

更新時間：2023-09-19

張鑾英Chang, Luan-Yin
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 10 個月

  • twffccy@gamil.com

Recruiting Trial

18Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張鑾英

List

49Cases

2009-08-10 - 2010-12-25

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2010-10-01 - 2011-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2012-09-30 - 2015-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2017-05-15 - 2019-05-31

Others

Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals’ human rotavirus (HRV) vaccine (444563), in healthy infants starting at age 6-12 weeks.

  • Condition/Disease

    Active immunisation of infants against gastroenteritis (GE) due to rotavirus (RV).

  • Test Drug

    HRV PCV-free vaccine

Participate Sites
6Sites

Terminated6Sites

2016-03-01 - 2018-10-31

Phase II

A phase II observer-blind, multicentre, dose-ranging study of children 6 to less than 36 months of age who are to be primed with a 2-dose series of GSK Biologicals’ AS03-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine

  • Condition/Disease

    Active immunization against influenza A virus H5N1 subtype

  • Test Drug

    GlaxoSmithKline (GSK) Biologicals’ Influenza A/Indonesia/05/2005 (H5N1) vaccine adjuvanted with AS03

Participate Sites
8Sites

Terminated7Sites

邱政洵
Linkou Chang Gung Medical Foundation

Division of Pediatrics

2016-12-13 - 2017-10-30

Phase III

A Phase III Study of Immunogenicity and Safety Evaluation of AdimFlu-S Quadrivalent Inactivated Influenza Vaccine (QIS) in Healthy Subjects Aged 3 Years Old to 17 Years Old

  • Condition/Disease

    Influenza

  • Test Drug

    Quadrivalent inactivated split (QIS) influenza vaccine (AdimFlu-S (QIS)

Participate Sites
2Sites

Terminated2Sites

2014-07-01 - 2017-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2009-09-20 - 2010-06-30

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2010-10-01 - 2011-06-30

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2016-02-01 - 2017-03-31

Phase II

An Open-Label, Dose-Finding, Phase II Study to Evaluate the Immunogenicity and Safety of the Bioreactor-generated EV71 Vaccine in Pediatric Subjects aged 3 to 6 years and 2 to 35 months old

  • Condition/Disease

    Enterovirus Infections (EV71)

  • Test Drug

    EV71 Vaccine

Participate Sites
1Sites

Terminated1Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB